eloralintide vs cagrilintide GLP-1 83588 Everyone and their mother is
Everyone and their mother is talking about eloralintide, the new amylin receptor agonist showing up to 20% body weight reduction in early trials. Gabriel Alizaidy, MD, MS Eloralintide Lilly's Amylin Agonist Outperforms Novo's Cagrilintide at 48 Weeks ADA2025: Eloralintide vs Cagri in Rats Selective amylin mimetic shows improved tolerability and lean mass preservation Preclinical head to head in lean & DIO rats Eloralintide: Similar weight loss to Introducing: Petrelintide Discover the Promise of Amylin Agonist Medications for Weight Loss Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
Pay in 4 interest-free payments of $5.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 16 - Sep 21



